BLACK DIAMOND THERAPEUTICS I

Insider buying by Black Diamond Therapeutics’ director signals confidence amid sharp price dips—potential entry point for long‑term investors.

Raman Prakash’s $1.66 buy of 7,907 Black Diamond Therapeutics shares shows insider confidence amid a “buy‑the‑dip” strategy, hinting at future upside in its genetically‑defined cancer focus.